Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 9 Researches
7.1
USERS' SCORE
Good
Based on 6 Reviews
8.1
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Iron (elemental) (from 90 mg Ferrous Bisglycinate)(Ferrochelâ„¢)
18 mg
100%
Top Medical Research Studies
9
We investigated how iron treatment affects iron levels and blood production in rats that underwent ovariectomy, a procedure mimicking menopause. By using Deferasirox, a medication often prescribed for iron overload conditions, we aimed to understand its role in managing iron levels and supporting blood health in this context.
Our study involved sixty-four female Wistar rats divided into several groups. After undergoing surgery to simulate menopause, we induced iron accumulation in them. We then treated some groups with Deferasirox at varying doses and looked into its effects on their health.
We observed that the treatment with Deferasirox led to improved conditions in several key areas. There were noticeable positive changes in the uterine tissue, an increase in white blood cells, and a decrease in harmful iron levels. Moreover, the treatment increased the body’s antioxidant capacity, helping fight oxidative stress commonly seen in menopausal conditions.
Deferasirox also had beneficial effects on bone health and the overall functioning of blood-producing cells. Additionally, it influenced gene expressions related to iron metabolism and blood production. Overall, we found that Deferasirox plays an important role in managing iron and enhancing blood health in rats experiencing conditions similar to menopause.
Our study involved sixty-four female Wistar rats divided into several groups. After undergoing surgery to simulate menopause, we induced iron accumulation in them. We then treated some groups with Deferasirox at varying doses and looked into its effects on their health.
We observed that the treatment with Deferasirox led to improved conditions in several key areas. There were noticeable positive changes in the uterine tissue, an increase in white blood cells, and a decrease in harmful iron levels. Moreover, the treatment increased the body’s antioxidant capacity, helping fight oxidative stress commonly seen in menopausal conditions.
Deferasirox also had beneficial effects on bone health and the overall functioning of blood-producing cells. Additionally, it influenced gene expressions related to iron metabolism and blood production. Overall, we found that Deferasirox plays an important role in managing iron and enhancing blood health in rats experiencing conditions similar to menopause.
9
We explored the effectiveness of echinochrome A (Ech A) in treating dry mouth, a common issue during menopause, using ovariectomized rats to simulate this condition. The study involved different groups of rats, including those treated with Ech A.
We observed that rats receiving Ech A showed improved salivary gland function compared to untreated ovariectomized rats. Key markers linked to dryness reduced significantly in the treated groups, suggesting Ech A may help in alleviating menopausal dry mouth by promoting salivation and reducing harmful effects on salivary tissues.
We observed that rats receiving Ech A showed improved salivary gland function compared to untreated ovariectomized rats. Key markers linked to dryness reduced significantly in the treated groups, suggesting Ech A may help in alleviating menopausal dry mouth by promoting salivation and reducing harmful effects on salivary tissues.
8
We explored how iron treatments can address salivary gland issues that often arise after menopause. By observing ovariectomized rats, we found that using deferoxamine and ferrostatin-1 helped reduce inflammation and reverse some damage to the salivary glands.
Both treatments improved the function of these glands and decreased harmful iron accumulation. However, more studies are needed to confirm their effectiveness in humans. Overall, the findings suggest potential new avenues for treating menopausal symptoms like dry mouth.
Both treatments improved the function of these glands and decreased harmful iron accumulation. However, more studies are needed to confirm their effectiveness in humans. Overall, the findings suggest potential new avenues for treating menopausal symptoms like dry mouth.
Most Useful Reviews
9
Less dizziness
I began taking this supplement as menopause caused significant dizziness, making it hard to get enough iron from meals. After two to three weeks, my dizziness has improved remarkably, and it has become infrequent. I plan to continue this regimen for a while.
7.5
Improved overall health
Previously, I occasionally took various iron products, but as I entered menopause, I began to feel dizzy and lightheaded. After reading Dr. Fujikawa's book, I discovered that this chelated iron is the most efficient for absorption, so I purchased it. I want to continue because iron is vital for health, and improving my anaemia alleviates numerous symptoms throughout my body. I choose the small 18ml size for easy consumption while avoiding over-intake.
7.5
Maintained good health
After menopause, I've learned about the importance of iron in nutrition. I now take one 18mg capsule after dinner to maintain my health. I feel in very good shape since starting this routine.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 9 Researches
7.1
- All Researches
9
We investigated how iron treatment affects iron levels and blood production in rats that underwent ovariectomy, a procedure mimicking menopause. By using Deferasirox, a medication often prescribed for iron overload conditions, we aimed to understand its role in managing iron levels and supporting blood health in this context.
Our study involved sixty-four female Wistar rats divided into several groups. After undergoing surgery to simulate menopause, we induced iron accumulation in them. We then treated some groups with Deferasirox at varying doses and looked into its effects on their health.
We observed that the treatment with Deferasirox led to improved conditions in several key areas. There were noticeable positive changes in the uterine tissue, an increase in white blood cells, and a decrease in harmful iron levels. Moreover, the treatment increased the body’s antioxidant capacity, helping fight oxidative stress commonly seen in menopausal conditions.
Deferasirox also had beneficial effects on bone health and the overall functioning of blood-producing cells. Additionally, it influenced gene expressions related to iron metabolism and blood production. Overall, we found that Deferasirox plays an important role in managing iron and enhancing blood health in rats experiencing conditions similar to menopause.
Our study involved sixty-four female Wistar rats divided into several groups. After undergoing surgery to simulate menopause, we induced iron accumulation in them. We then treated some groups with Deferasirox at varying doses and looked into its effects on their health.
We observed that the treatment with Deferasirox led to improved conditions in several key areas. There were noticeable positive changes in the uterine tissue, an increase in white blood cells, and a decrease in harmful iron levels. Moreover, the treatment increased the body’s antioxidant capacity, helping fight oxidative stress commonly seen in menopausal conditions.
Deferasirox also had beneficial effects on bone health and the overall functioning of blood-producing cells. Additionally, it influenced gene expressions related to iron metabolism and blood production. Overall, we found that Deferasirox plays an important role in managing iron and enhancing blood health in rats experiencing conditions similar to menopause.
9
We explored the effectiveness of echinochrome A (Ech A) in treating dry mouth, a common issue during menopause, using ovariectomized rats to simulate this condition. The study involved different groups of rats, including those treated with Ech A.
We observed that rats receiving Ech A showed improved salivary gland function compared to untreated ovariectomized rats. Key markers linked to dryness reduced significantly in the treated groups, suggesting Ech A may help in alleviating menopausal dry mouth by promoting salivation and reducing harmful effects on salivary tissues.
We observed that rats receiving Ech A showed improved salivary gland function compared to untreated ovariectomized rats. Key markers linked to dryness reduced significantly in the treated groups, suggesting Ech A may help in alleviating menopausal dry mouth by promoting salivation and reducing harmful effects on salivary tissues.
8
We looked into how iron levels affect cognitive performance in women experiencing menopause. Our research involved non-anemic women who had either low or normal iron levels for their age and background. They provided blood samples, underwent MRI scans to assess brain iron levels, and participated in cognitive tasks while we recorded their brain activity through EEG.
What we found was quite interesting. Higher iron status in these women was linked to better cognitive performance and improved brain activity. This included benefits associated with oxygen transport, which is crucial for brain function. However, we didn’t discover any direct connections between iron levels in the blood and the iron present in the brain.
Despite the lack of a clear relationship between systemic and brain iron, our findings suggest that addressing low iron levels during the menopausal transition may help reduce the cognitive struggles, often referred to as "brain fog," that many women experience during this time. So, while the study didn’t evaluate specific iron treatments, it opens the door to thinking about iron status as a factor worth considering for overall cognitive health in menopausal women.
What we found was quite interesting. Higher iron status in these women was linked to better cognitive performance and improved brain activity. This included benefits associated with oxygen transport, which is crucial for brain function. However, we didn’t discover any direct connections between iron levels in the blood and the iron present in the brain.
Despite the lack of a clear relationship between systemic and brain iron, our findings suggest that addressing low iron levels during the menopausal transition may help reduce the cognitive struggles, often referred to as "brain fog," that many women experience during this time. So, while the study didn’t evaluate specific iron treatments, it opens the door to thinking about iron status as a factor worth considering for overall cognitive health in menopausal women.
8
We explored how iron treatments can address salivary gland issues that often arise after menopause. By observing ovariectomized rats, we found that using deferoxamine and ferrostatin-1 helped reduce inflammation and reverse some damage to the salivary glands.
Both treatments improved the function of these glands and decreased harmful iron accumulation. However, more studies are needed to confirm their effectiveness in humans. Overall, the findings suggest potential new avenues for treating menopausal symptoms like dry mouth.
Both treatments improved the function of these glands and decreased harmful iron accumulation. However, more studies are needed to confirm their effectiveness in humans. Overall, the findings suggest potential new avenues for treating menopausal symptoms like dry mouth.
8
Impact of periodontal therapy on ferritin
We investigated the impact of non-surgical periodontal therapy on serum ferritin levels in postmenopausal women dealing with chronic periodontitis.
In our cross-sectional study with 38 women, we measured ferritin levels and periodontal health before and three months after treatment.
Interestingly, we found that serum ferritin decreased significantly from 108.55 mcg/L to 98.28 mcg/L after therapy.
Alongside this, improvements in gum health were also noteworthy, showcasing that periodontal care can play an essential role in managing ferritin levels post-menopause.
In our cross-sectional study with 38 women, we measured ferritin levels and periodontal health before and three months after treatment.
Interestingly, we found that serum ferritin decreased significantly from 108.55 mcg/L to 98.28 mcg/L after therapy.
Alongside this, improvements in gum health were also noteworthy, showcasing that periodontal care can play an essential role in managing ferritin levels post-menopause.
User Reviews
USERS' SCORE
Good
Based on 6 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
9
Less dizziness
I began taking this supplement as menopause caused significant dizziness, making it hard to get enough iron from meals. After two to three weeks, my dizziness has improved remarkably, and it has become infrequent. I plan to continue this regimen for a while.
7.5
Improved overall health
Previously, I occasionally took various iron products, but as I entered menopause, I began to feel dizzy and lightheaded. After reading Dr. Fujikawa's book, I discovered that this chelated iron is the most efficient for absorption, so I purchased it. I want to continue because iron is vital for health, and improving my anaemia alleviates numerous symptoms throughout my body. I choose the small 18ml size for easy consumption while avoiding over-intake.
7.5
Maintained good health
After menopause, I've learned about the importance of iron in nutrition. I now take one 18mg capsule after dinner to maintain my health. I feel in very good shape since starting this routine.
8
No stomach discomfort
1 people found this helpful
I became anemic during menstruation, but now that I'm in menopause, this iron supplement has greatly aided me. It has been one of the few iron supplements that does not cause stomach discomfort, even without taking stomach medication.
6
Dizziness reduction
During menopause, my cycle became irregular, and I faced excessive menstrual bleeding. I purchased this supplement due to worsening anaemia and dizziness. I only take it before and during my period to avoid constipation, and I've noticed improvements in both my anaemia and dizziness since starting it.
Frequently Asked Questions
9
Less dizziness
I began taking this supplement as menopause caused significant dizziness, making it hard to get enough iron from meals. After two to three weeks, my dizziness has improved remarkably, and it has become infrequent. I plan to continue this regimen for a while.
6
Fatigue relief
1 people found this helpful
When feeling tired, I wondered if I was anemic, so I tried this supplement for a few days and noticed an improvement in how I felt. I also felt warmer. Approaching 50, I recommend it for anyone going through menopause and experiencing physical issues. Taking iron is crucial to avoid deficiencies.
7.5
Improved overall health
Previously, I occasionally took various iron products, but as I entered menopause, I began to feel dizzy and lightheaded. After reading Dr. Fujikawa's book, I discovered that this chelated iron is the most efficient for absorption, so I purchased it. I want to continue because iron is vital for health, and improving my anaemia alleviates numerous symptoms throughout my body. I choose the small 18ml size for easy consumption while avoiding over-intake.
6
Dizziness reduction
During menopause, my cycle became irregular, and I faced excessive menstrual bleeding. I purchased this supplement due to worsening anaemia and dizziness. I only take it before and during my period to avoid constipation, and I've noticed improvements in both my anaemia and dizziness since starting it.
8
No stomach discomfort
1 people found this helpful
I became anemic during menstruation, but now that I'm in menopause, this iron supplement has greatly aided me. It has been one of the few iron supplements that does not cause stomach discomfort, even without taking stomach medication.
7.5
Maintained good health
After menopause, I've learned about the importance of iron in nutrition. I now take one 18mg capsule after dinner to maintain my health. I feel in very good shape since starting this routine.
8
We looked into how iron levels affect cognitive performance in women experiencing menopause. Our research involved non-anemic women who had either low or normal iron levels for their age and background. They provided blood samples, underwent MRI scans to assess brain iron levels, and participated in cognitive tasks while we recorded their brain activity through EEG.
What we found was quite interesting. Higher iron status in these women was linked to better cognitive performance and improved brain activity. This included benefits associated with oxygen transport, which is crucial for brain function. However, we didn’t discover any direct connections between iron levels in the blood and the iron present in the brain.
Despite the lack of a clear relationship between systemic and brain iron, our findings suggest that addressing low iron levels during the menopausal transition may help reduce the cognitive struggles, often referred to as "brain fog," that many women experience during this time. So, while the study didn’t evaluate specific iron treatments, it opens the door to thinking about iron status as a factor worth considering for overall cognitive health in menopausal women.
What we found was quite interesting. Higher iron status in these women was linked to better cognitive performance and improved brain activity. This included benefits associated with oxygen transport, which is crucial for brain function. However, we didn’t discover any direct connections between iron levels in the blood and the iron present in the brain.
Despite the lack of a clear relationship between systemic and brain iron, our findings suggest that addressing low iron levels during the menopausal transition may help reduce the cognitive struggles, often referred to as "brain fog," that many women experience during this time. So, while the study didn’t evaluate specific iron treatments, it opens the door to thinking about iron status as a factor worth considering for overall cognitive health in menopausal women.
7
We examined the connection between iron levels and cognitive performance in women going through menopause. Non-anemic participants, with varying iron levels, provided blood samples and completed cognitive tests while brain scans measured iron content.
Our findings revealed that higher iron levels were linked to improved cognitive abilities. However, we did not observe a direct relationship between systemic iron and brain iron levels.
This suggests that increasing iron might be a viable strategy to help combat the "brain fog" that often accompanies menopause.
Our findings revealed that higher iron levels were linked to improved cognitive abilities. However, we did not observe a direct relationship between systemic iron and brain iron levels.
This suggests that increasing iron might be a viable strategy to help combat the "brain fog" that often accompanies menopause.
4
We explored the relationship between iron biomarkers and menopausal status in a study involving over 3,800 women from the CoLaus and PREVEND cohorts. By assessing markers like ferritin and transferrin, we found that these could provide additional insights for distinguishing menopausal women from those who aren’t, beyond just age.
Interestingly, the inclusion of these markers improved the predictive model for menopause classification, albeit modestly. While our results are promising, further investigation is needed especially on hepcidin levels.
Interestingly, the inclusion of these markers improved the predictive model for menopause classification, albeit modestly. While our results are promising, further investigation is needed especially on hepcidin levels.
7
We explored the relationship between iron accumulation and the effectiveness of hormone replacement therapy (HRT) in postmenopausal women facing atherosclerosis.
Our findings indicated that excess iron can hinder estrogen receptor activity, reducing the effectiveness of HRT.
In a mouse model, we noted that combining estradiol treatment with iron further diminished estrogen receptor expression and worsened atherosclerosis.
Interestingly, iron chelation showed promise in alleviating the issues caused by HRT ineffectiveness in late postmenopausal stages. Thus, managing iron levels may enhance HRT benefits for some women.
Our findings indicated that excess iron can hinder estrogen receptor activity, reducing the effectiveness of HRT.
In a mouse model, we noted that combining estradiol treatment with iron further diminished estrogen receptor expression and worsened atherosclerosis.
Interestingly, iron chelation showed promise in alleviating the issues caused by HRT ineffectiveness in late postmenopausal stages. Thus, managing iron levels may enhance HRT benefits for some women.
4
We explored how iron accumulation affects bone health in estrogen-deficient rats. After performing ovariectomy to mimic menopause, we noted significant changes in iron metabolism. Although iron levels initially decreased, adding ferric ammonium citrate led to higher iron content and resulted in accelerated bone loss.
Importantly, our findings showed that iron did not accumulate as expected in the ovariectomized rats. Instead, the presence of excess iron worsened bone loss by increasing bone resorption. This suggests that managing iron levels might be crucial for maintaining bone health post-menopause.
Importantly, our findings showed that iron did not accumulate as expected in the ovariectomized rats. Instead, the presence of excess iron worsened bone loss by increasing bone resorption. This suggests that managing iron levels might be crucial for maintaining bone health post-menopause.
9
We investigated how iron treatment affects iron levels and blood production in rats that underwent ovariectomy, a procedure mimicking menopause. By using Deferasirox, a medication often prescribed for iron overload conditions, we aimed to understand its role in managing iron levels and supporting blood health in this context.
Our study involved sixty-four female Wistar rats divided into several groups. After undergoing surgery to simulate menopause, we induced iron accumulation in them. We then treated some groups with Deferasirox at varying doses and looked into its effects on their health.
We observed that the treatment with Deferasirox led to improved conditions in several key areas. There were noticeable positive changes in the uterine tissue, an increase in white blood cells, and a decrease in harmful iron levels. Moreover, the treatment increased the body’s antioxidant capacity, helping fight oxidative stress commonly seen in menopausal conditions.
Deferasirox also had beneficial effects on bone health and the overall functioning of blood-producing cells. Additionally, it influenced gene expressions related to iron metabolism and blood production. Overall, we found that Deferasirox plays an important role in managing iron and enhancing blood health in rats experiencing conditions similar to menopause.
Our study involved sixty-four female Wistar rats divided into several groups. After undergoing surgery to simulate menopause, we induced iron accumulation in them. We then treated some groups with Deferasirox at varying doses and looked into its effects on their health.
We observed that the treatment with Deferasirox led to improved conditions in several key areas. There were noticeable positive changes in the uterine tissue, an increase in white blood cells, and a decrease in harmful iron levels. Moreover, the treatment increased the body’s antioxidant capacity, helping fight oxidative stress commonly seen in menopausal conditions.
Deferasirox also had beneficial effects on bone health and the overall functioning of blood-producing cells. Additionally, it influenced gene expressions related to iron metabolism and blood production. Overall, we found that Deferasirox plays an important role in managing iron and enhancing blood health in rats experiencing conditions similar to menopause.
References
- Barnett AL, Wenger MJ, Miles P, Wu D, Isingizwe ZR, et al. Cognitive Performance in Relation to Systemic and Brain Iron at Perimenopause. medRxiv. 2025. 10.1101/2025.01.28.25321122
- Honari N, Sayadi M, Sajjadi SM, Solhjoo S, Sarab GA. Deferasirox improved iron homeostasis and hematopoiesis in ovariectomized rats with iron accumulation. Sci Rep. 2025;15:2449. 10.1038/s41598-025-86333-z
- Barnett AL, Wenger MJ, Miles P, Wu D, Isingizwe ZR, et al. Cognitive Performance in Relation to Systemic and Brain Iron at Perimenopause. Nutrients. 2025;17. 10.3390/nu17050745
- Kastrati L, Groothof D, Quezada-Pinedo HG, Raeisi-Dehkordi H, Bally L, et al. Utility of iron biomarkers in differentiating menopausal status: Findings from CoLaus and PREVEND. Maturitas. 2024;179:107872. 10.1016/j.maturitas.2023.107872
- Xu T, Cai J, Wang L, Xu L, Zhao H, et al. Hormone replacement therapy for postmenopausal atherosclerosis is offset by late age iron deposition. Elife. 2023;12. 10.7554/eLife.80494
- Cheon YI, Kim JM, Shin SC, Kim HS, Lee JC, et al. Effect of deferoxamine and ferrostatin-1 on salivary gland dysfunction in ovariectomized rats. Aging (Albany NY). 2023;15:2418. 10.18632/aging.204641
- Kim JM, Shin SC, Cheon YI, Kim HS, Park GC, et al. Effect of Echinochrome A on Submandibular Gland Dysfunction in Ovariectomized Rats. Mar Drugs. 2022;20. 10.3390/md20120729
- Faramarzi M, Shirmohammadi A, Khorramdel A, Sadighi M, Bargahi E. Effect of non-surgical periodontal therapy on serum ferritin levels in postmenopausal women with chronic periodontitis. J Dent Res Dent Clin Dent Prospects. 2021;15:178. 10.34172/joddd.2021.030
- Liu LL, Liu GW, Liu H, Zhao K, Xu YJ. Iron accumulation deteriorated bone loss in estrogen-deficient rats. J Orthop Surg Res. 2021;16:525. 10.1186/s13018-021-02663-4
